A Two-Arm, Open-Label, Randomized, Multi-Center Pharmacokinetic and Long-Term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men.
Phase of Trial: Phase III
Latest Information Update: 09 Mar 2017
At a glance
- Drugs Testosterone undecanoate (Primary)
- Indications Hypogonadism
- Focus Pharmacokinetics; Registrational
- Sponsors Endo Pharmaceuticals Solutions
- 31 Aug 2018 Biomarkers information updated
- 29 Nov 2007 The NDA action date has been set for 27 Jun 2008.
- 07 Jun 2007 Status change from in progress to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History